Clinical trials: Stage IV, NSCLC
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
This phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and neck cancer that has spread to other places in the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01727076
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV
This study wants to determine the activity of a first-line treatment related to Thymidylate Synthetase (TS) Expression. Patients with the diagnosis of non-squamous advanced Non-Small-Cell Lung-Cancer (Stage IV) and without…
- Trial name
- SELECT-A (NCT01674738)
- Testing
- Pemetrexed, Cisplatin, Bevacizumab
- Sponsor
- Aktion Bronchialkarzinom e.V.
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer
This clinical trial refines and tests the effect of a decision aid in improving decision-making in patients with non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Trial name
- NCT04946279
- Testing
- Best Practice, Informational Intervention, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02520778
- Testing
- Navitoclax, Osimertinib
- Where
- 18 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
The aim of this study is to combine AZD1775 with standard front-line chemotherapy in subjects with advanced NSCLC.
- Trial name
- NCT02087241
- Testing
- AZD1775, pemetrexed, carboplatin
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.
- Trial name
- NCT03003468
- Testing
- Imprime PGG, MK-3475
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Lawrence Feldman, MD
Non Small Cell Lung Cancer
Dendritic Cells in Lung Cancer
Vaccination with autologous dendritic cells pulsed with allogeneic melanoma cell lysate (MelCancerVac) in combination with the Cox-2 inhibitor of celecoxib for the treatment of patients with advanced or metastatic non-small cell…
- Trial name
- NCT00442754
- Testing
- Allogeneic Tumour Lysate (MelCancerVac)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Herlev Hospital
Non-small Cell Lung Cancer Metastatic
An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC
This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of Oba01 for injection in patients with DR5 positive LA/mNSCLC.
- Trial name
- NCT06083870
- Testing
- Oba01
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Lu Shun
Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung…
- Conditions
- Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
- Trial name
- NCT05681780
- Testing
- Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC
The purpose of this study is to determine whether continuing erlotinib beyond disease progression in combination with chemotherapy is beneficial for NSCLC patients who have EGFR mutant disease or who have responded to EGFR TKI.
- Trial name
- NCT02064491
- Testing
- Erlotinib, Chemotherapy
- Where
- 7 sites in Finland
- Volunteers
- 18 people
- Sponsor
- Finnish Lung Cancer Group
Non-Small-Cell Lung Cancer
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy.
- Trial name
- CheckMate 568 (NCT02659059)
- Testing
- Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy
- Where
- 32 sites in United States, Canada
- Volunteers
- 324 people
- Sponsor
- Bristol-Myers Squibb
Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or…
- Conditions
- Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer
- Trial name
- NCT02567396
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00030641
- Testing
- oblimersen sodium, docetaxel
- Where
- 44 sites in United States, Canada and 1 more
- Sponsor
- Genta Incorporated
Non-Small-Cell Lung Carcinoma
A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to find a safe and effective dose of Erbitux and Iressa for subject with non small cell lung cancer.
- Trial name
- NCT00162318
- Testing
- Cetuximab + Gefitinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Lung Non-Small Cell Carcinoma
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer.
- Trial name
- NCT06116682
- Testing
- Amivantamab, Biospecimen Collection, Computed Tomography
- Where
- 271 sites in United States
- Volunteers
- 88 people
- Sponsor
- SWOG Cancer Research Network
NSCLC
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
This single-arm, multi-center study is to evaluate Sugemalimab plus platinum-based chemotherapy as first-line therapy for patients with locally advanced and metastatic NSCLC in a real-world setting.
- Trial name
- NCT07247227
- Testing
- Sugemalimab and Chemotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking Union Medical College
Carcinoma, Non Small Cell Lung
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer
Phase 2 study to investigate the efficacy and tolerability of epothilone ZK 219477 in patients with stage IIIb or stage IV non-small-cell lung cancer.
- Trial name
- NCT00160069
- Testing
- Sagopilone (BAY86-5302, ZK 219477)
- Where
- 17 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Bayer
Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of FR901228 in treating patients who have refractory or…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Trial name
- NCT00020202
- Testing
- FR901228
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
In this study, participants with programmed cell death ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) will be randomized to receive single agent pembrolizumab for up to 35 treatments or standard of care (SOC)…
- Trial name
- NCT02220894
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Volunteers
- 1,274 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, NSCLC
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of D-0316 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor…
- Conditions
- Solid Tumor, NSCLC, EGFR T790M
- Trial name
- NCT03861156
- Testing
- D-0316
- Where
- China
- Volunteers
- 290 people
- Sponsor
- InventisBio Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.